Crossject
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster he… Read more
Crossject (ALCJ) - Net Assets
Latest net assets as of June 2025: €-1.12 Million EUR
Based on the latest financial reports, Crossject (ALCJ) has net assets worth €-1.12 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€31.38 Million) and total liabilities (€32.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-1.12 Million |
| % of Total Assets | -3.56% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -130.38% |
| Growth Volatility | 506.54 |
Crossject - Net Assets Trend (2010–2024)
This chart illustrates how Crossject's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Crossject (2010–2024)
The table below shows the annual net assets of Crossject from 2010 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-2.67 Million | +49.27% |
| 2023-12-31 | €-5.27 Million | -296.17% |
| 2022-12-31 | €2.69 Million | +149.01% |
| 2021-12-31 | €-5.48 Million | -384.99% |
| 2020-12-31 | €-1.13 Million | -137.50% |
| 2019-12-31 | €3.01 Million | +82.16% |
| 2018-12-31 | €1.65 Million | -72.81% |
| 2017-12-31 | €6.09 Million | -3.15% |
| 2016-12-31 | €6.28 Million | -28.57% |
| 2015-12-31 | €8.80 Million | -39.26% |
| 2014-12-31 | €14.48 Million | +1428.46% |
| 2013-12-31 | €947.65K | +149.75% |
| 2012-12-31 | €-1.90 Million | +11.29% |
| 2011-12-31 | €-2.15 Million | +74.40% |
| 2010-12-31 | €-8.39 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Crossject's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1388676100.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €4.55 Million | % |
| Other Comprehensive Income | €972.00K | % |
| Other Components | €7.19 Million | % |
| Total Equity | €-2.67 Million | 100.00% |
Crossject Competitors by Market Cap
The table below lists competitors of Crossject ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Meteoric Resources NL
OTCGREY:METOF
|
$105.49 Million |
|
SMARTOPTICS GRP AS NK-02
F:3YL
|
$105.49 Million |
|
Bombay Dyeing & Mfg Company Limited
NSE:BOMDYEING
|
$105.52 Million |
|
Lealea Enterprise Co Ltd
TW:1444
|
$105.55 Million |
|
Fury Gold Mines Ltd
NYSE MKT:FURY
|
$105.47 Million |
|
Altius Renewable Royalties Corp
OTCQX:ATRWF
|
$105.47 Million |
|
Laxmi Organic Industries Limited
NSE:LXCHEM
|
$105.45 Million |
|
First Ottawa Bancshares Inc
PINK:FOTB
|
$105.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Crossject's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -5,269,000 to -2,673,000, a change of 2,596,000.
- Net loss of 12,795,000 reduced equity.
- Share repurchases of 878,000 reduced equity.
- New share issuances of 15,085,000 increased equity.
- Other comprehensive income increased equity by 962,999.
- Other factors increased equity by 221,001.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-12.79 Million | -478.68% |
| Share Repurchases | €878.00K | -32.85% |
| Share Issuances | €15.09 Million | +564.35% |
| Other Comprehensive Income | €963.00K | +36.03% |
| Other Changes | €221.00K | +8.27% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares Crossject's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | €-1.89 | €2.09 | x |
| 2011-12-31 | €-0.48 | €2.09 | x |
| 2012-12-31 | €-0.43 | €2.09 | x |
| 2013-12-31 | €0.18 | €2.09 | x |
| 2014-12-31 | €2.18 | €2.09 | x |
| 2015-12-31 | €1.32 | €2.09 | x |
| 2016-12-31 | €0.86 | €2.09 | x |
| 2017-12-31 | €0.68 | €2.09 | x |
| 2018-12-31 | €0.12 | €2.09 | x |
| 2019-12-31 | €0.15 | €2.09 | x |
| 2020-12-31 | €-0.05 | €2.09 | x |
| 2021-12-31 | €-0.24 | €2.09 | x |
| 2022-12-31 | €0.06 | €2.09 | x |
| 2023-12-31 | €-0.14 | €2.09 | x |
| 2024-12-31 | €-0.06 | €2.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Crossject utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -310.94%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-130.37%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 0.00% | -2058.76% | 0.07x | 0.00x | €-3.28 Million |
| 2011 | 0.00% | 237.75% | 0.22x | 0.00x | €1.76 Million |
| 2012 | 0.00% | -261.88% | 0.14x | 0.00x | €-735.29K |
| 2013 | -192.33% | -194.74% | 0.17x | 5.96x | €-1.92 Million |
| 2014 | -29.94% | -313.04% | 0.08x | 1.27x | €-5.78 Million |
| 2015 | -64.64% | -358.57% | 0.11x | 1.58x | €-6.57 Million |
| 2016 | -106.03% | -468.32% | 0.10x | 2.27x | €-7.29 Million |
| 2017 | -125.06% | -235.32% | 0.18x | 2.91x | €-8.22 Million |
| 2018 | -647.41% | -438.26% | 0.12x | 12.18x | €-10.88 Million |
| 2019 | -238.02% | -1434.74% | 0.02x | 8.13x | €-7.48 Million |
| 2020 | 0.00% | -203.22% | 0.14x | 0.00x | €-9.73 Million |
| 2021 | 0.00% | -1184.87% | 0.03x | 0.00x | €-10.19 Million |
| 2022 | -552.05% | -1169.50% | 0.03x | 16.26x | €-11.36 Million |
| 2023 | 0.00% | -5957.24% | 0.01x | 0.00x | €-8.11 Million |
| 2024 | 0.00% | -310.94% | 0.13x | 0.00x | €-12.53 Million |
Industry Comparison
This section compares Crossject's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $692,539,849
- Average return on equity (ROE) among peers: -307.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Crossject (ALCJ) | €-1.12 Million | 0.00% | N/A | $105.49 Million |
| I.Ceram SA (ALICR) | $2.61 Million | -58.47% | 1.19x | $95.27K |
| Safe Orthopaedics SA (ALSAF) | $398.00K | -1685.68% | 36.39x | $139.52K |
| Spineway (ALSPW) | $22.01 Million | -14.25% | 0.26x | $6.68 Million |
| Amplitude Surgical SAS (AMPLI) | $85.50 Million | -10.51% | 2.27x | $14.07 Million |
| EssilorLuxottica S. A. (EL) | $4.04 Billion | 14.67% | 0.88x | $61.18 Billion |
| Bonyf NV (MLBON) | $3.73 Million | -89.06% | 0.12x | $43.34K |